Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241189 · ClinicalTrials.gov registry record · Phase 1
Rapamycin vs Methotrexate in Diffuse SSc
A Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00241189 is a Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 17 participants.
The verdict
NCT00241189, a Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a study to determine the safety of the immunosuppressive rapamycin in patients with systemic sclerosis with diffuse cutaneous scleroderma. The effects (both good and bad) are being compared to another group of systemic sclerosis patients receiving methotrexate
Interventions
- DRUG rapamycin
- DRUG methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2002-08 |
| Est. Completion | 2006-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00241189
The ClinicalTrials.gov registry entry for NCT00241189 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rapamycin is the first listed.
NCT00241189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00241189 about?
NCT00241189 is a clinical study titled "Rapamycin vs Methotrexate in Diffuse SSc". This is a study to determine the safety of the immunosuppressive rapamycin in patients with systemic sclerosis with diffuse cutaneous scleroderma. The effects (both good and bad) are being compared to another group of systemic sclerosis patients receiving methotrexate
What is the current status of trial NCT00241189?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2002-08. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00241189?
The interventions under investigation include: rapamycin (DRUG), methotrexate (DRUG).
Who is sponsoring clinical trial NCT00241189?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.